Filtered By:
Cancer: Melanoma
Vaccination: Influenza Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 26 results found since Jan 2013.
Biomaterial-based delivery platforms for transdermal immunotherapy
Biomed Pharmacother. 2023 Jun 27;165:115048. doi: 10.1016/j.biopha.2023.115048. Online ahead of print.ABSTRACTNowadays, immunotherapy is one of the most essential treatments for various diseases and a broad spectrum of disorders are assumed to be treated by altering the function of the immune system. For this reason, immunotherapy has attracted a great deal of attention and numerous studies on different approaches for immunotherapies have been investigated, using multiple biomaterials and carriers, from nanoparticles (NPs) to microneedles (MNs). In this review, the immunotherapy strategies, biomaterials, devices, and disea...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 29, 2023 Category: Drugs & Pharmacology Authors: Mohammad Dahri Nima Beheshtizadeh Nasrin Seyedpour Amin Nakhostin-Ansari Faezeh Aghajani Simin Seyedpour Moein Masjedi Fatemeh Farjadian Reza Maleki Khosro Adibkia Source Type: research
Immunogenicity of COVID-19 vaccination in melanoma patients under immune checkpoint blockade
CONCLUSION: Melanoma patients under ICI therapy show comparable antibody response after SARS CoV-2 vaccination to healthy health care professionals. This finding is independent of the timing of ICI therapy.PMID:35609553 | DOI:10.1159/000524894
Source: Oncology - May 24, 2022 Category: Cancer & Oncology Authors: Jacqueline Niewolik Marie Mikuteit Anne Cossmann Kai Vahldiek Ralf Gutzmer Frank M üller Dominik Schr öder Stephanie Heinemann Georg M N Behrens Alexandra Dopfer-Jablonka Sandra Steffens Imke Grimmelmann Source Type: research
CD4 < sup > + < /sup > T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
CONCLUSION: CD4+ T cell epitope-based heterologous prime-boost vaccination elicited potent both tumor-specific TH1 and CTL response, leading to the efficient tumor control. This strategy can also potentiate PD-1/PD-L1 immune checkpoint blockade (ICB) against cancer.PMID:35580929 | DOI:10.1136/jitc-2021-004022
Source: Cancer Control - May 17, 2022 Category: Cancer & Oncology Authors: Minglu Xiao Luoyingzi Xie Guoshuai Cao Shun Lei Pengcheng Wang Zhengping Wei Yuan Luo Jingyi Fang Xingxing Yang Qizhao Huang Lifan Xu Junyi Guo Shuqiong Wen Zhiming Wang Qing Wu Jianfang Tang Lisha Wang Xiangyu Chen Cheng Chen Yanyan Zhang Wei Yao Jianqia Source Type: research
